Gemzar

(Gemcitabine)

ApprovedSmall molecule

Gemcitabine is a chemotherapy drug used to treat certain types of cancer, including pancreatic cancer, breast cancer, and lung cancer, by slowing or stopping the growth of cancer cells.[2] Gemzar is currently approved and in use across 168 indications[4].[1]

Gemzar is one of 1563 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Approved.

168

Indications

1,551

Total Trials

Active Trials

1,562

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Intrahepatic CholangiocarcinomaWithdrawn

Ovarian CancerUnknown status

Diffuse Large B-Cell LymphomaActive, not recruiting

CholangiocarcinomaRecruiting

Triple-Negative Breast CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaTerminated

Biliary Tract CancerCompleted

Urothelial CarcinomaCompleted

Metastatic Colorectal CancerCompleted

Breast CancerTerminated

Intrahepatic CholangiocarcinomaPhase 2

Withdrawn

Ovarian CancerPhase 3

Unknown status

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

CholangiocarcinomaPhase 3

Recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Terminated

Biliary Tract CancerPhase 3

Completed

Urothelial CarcinomaPhase 3

Completed

Metastatic Colorectal CancerPhase 2

Completed

Breast CancerPhase 3

Terminated

Showing 10 of 168 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Approved

88 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Duragesic

CCephalon

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Rilvegostomig

AstraZeneca

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05498220

Phase 2Active, not recruiting

Nasopharyngeal Carcinoma

NCT04517214

Phase 2Recruiting

Leiomyosarcoma

NCT04383119

Q1 2027

Phase 3Active, not recruiting

Triple-Negative Breast Cancer

NCT05382286

Q2 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06531447

Phase 3Recruiting

Lymphoma

NCT06230224

Clinical

Trials by Indication[1]

Pancreatic Cancer39 trials

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02194829·8 enrolled

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Withdrawn·HHitendra Patel·Phase 1/2·NCT03697239

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT00761345·27 enrolled

Show 36 more trials

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00398086·67 enrolled

Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT01048320·36 enrolled

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Completed· EMD Serono logo

EMD Serono·Phase 1/2·NCT01016483·141 enrolled

Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191568·45 enrolled

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT01663272·12 enrolled

Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Unknown status·CCrystalGenomics, Inc.·Phase 1/2·NCT02737228·24 enrolled

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche··NCT01782690·338 enrolled

Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

Temporarily not available·NNovoCure GmbH··NCT07319910

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02138383·25 enrolled

Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT02806687·68 enrolled

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

Unknown status·SSamsung Pharmaceutical Co., Ltd.·Phase 3·NCT02854072·148 enrolled

Masitinib Plus Gemcitabine in Pancreatic Cancer

Completed·AAB Science·Phase 3·NCT03766295·377 enrolled

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Terminated· Biogen logo

Biogen·Phase 1·NCT00529113·33 enrolled

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Unknown status·FFudan University·Phase 3·NCT04835064·600 enrolled

Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

Unknown status·AAzienda Ospedaliero, Universitaria Pisana·Phase 3·NCT02355119·310 enrolled

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00673504·105 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02155088·15 enrolled

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Completed·—·Phase 1·NCT01908478·34 enrolled

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Completed· Ipsen logo

Ipsen·Phase 3·NCT04083235·770 enrolled

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03693677·288 enrolled

GTX-RT in Borderline Resectable Pancreatic Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01754623·9 enrolled

A Study of Locally Advanced Pancreatic Cancer

Unknown status·NNational Health Research Institutes, Taiwan·Phase 2·NCT01063192·73 enrolled

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Completed·JJoseph J. Cullen·Phase 1·NCT01852890·16 enrolled

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche·Phase 2·NCT00652366·467 enrolled

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Active, not recruiting·DDo-Youn Oh·Phase 2·NCT03572400·71 enrolled

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01964534·114 enrolled

Chemoimmunotherapy and Radiation in Pancreatic Cancer

Completed·PProvidence Health & Services·Phase 1·NCT01903083·10 enrolled

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

Unknown status·RRuijin Hospital·Phase 2·NCT05185869·58 enrolled

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Completed·TTraws Pharma, Inc.·Phase 3·NCT01360853·160 enrolled

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276744·249 enrolled

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 1·NCT00593008·5 enrolled

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1/2·NCT06662669·120 enrolled

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Completed·GGeorge Albert Fisher·Phase 1·NCT00547144·2 enrolled

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Terminated·WWestern Regional Medical Center·Phase 2·NCT01851174·15 enrolled

Breast Cancer18 trials

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer

Unknown status·KKorean Breast Cancer Study Group·Phase 2·NCT01352494·99 enrolled

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04745975·100 enrolled

Show 15 more trials

Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00431106·144 enrolled

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting·TThe National Center of Oncology, Azerbaijan·Phase 2·NCT06531447·200 enrolled

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Completed·NNektar Therapeutics·Phase 3·NCT02915744·178 enrolled

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191672·120 enrolled

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Completed· Gilead logo

Gilead·Phase 3·NCT03901339·543 enrolled

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02755272·87 enrolled

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00623233·52 enrolled

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Not yet recruiting·FFudan University·Phase 2/3·NCT07366840·268 enrolled

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

Active, not recruiting·CCantargia AB·Phase 1/2·NCT05181462·117 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02819518·882 enrolled

Gemcitabine + Carboplatin in Breast Cancer

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00450762

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06081959·376 enrolled

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT04739670·31 enrolled

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00334802·62 enrolled

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT01045304·163 enrolled

Non-Small Cell Lung Cancer15 trials

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00215930·53 enrolled

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01160744·280 enrolled

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

Show 12 more trials

A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Completed· Roche logo

Roche·Phase 2·NCT01998919·154 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Completed·HHospices Civils de Lyon·Phase 3·NCT00300586·842 enrolled

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193362·200 enrolled

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Terminated· Roche logo

Roche·Phase 3·NCT02409355·8 enrolled

The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

Completed·FFudan University·Phase 2·NCT01797913·70 enrolled

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Terminated·NNewLink Genetics Corporation·Phase 2/3·NCT01774578·135 enrolled

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Completed·KKentuckiana Cancer Institute·N/A·NCT00283478·20 enrolled

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

Completed·NNational Taiwan University Hospital·Phase 2·NCT00154739·86 enrolled

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Completed·SStanford University·Phase 2·NCT00323869·48 enrolled

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Completed·—·Phase 2·NCT02303977·37 enrolled

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

Bladder Cancer10 trials

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03093922·32 enrolled

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Unknown status·—·N/A·NCT05626101·280 enrolled

Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer

Completed·UUniversity Of Perugia·Phase 1/2·NCT00696579·64 enrolled

Show 7 more trials

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Terminated· Eisai logo

Eisai·Phase 1/2·NCT01126749·92 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04241185·520 enrolled

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Completed·DDr Anders Ullén·Phase 2·NCT02665039·62 enrolled

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00585689·29 enrolled

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT02177695·237 enrolled

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00101842·61 enrolled

Pancreatic Adenocarcinoma10 trials

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting·UUniversity of Louisville·Phase 1·NCT03484299·20 enrolled

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Completed· Gilead logo

Gilead·Phase 2·NCT01472198·250 enrolled

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00558207·43 enrolled

Show 7 more trials

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Completed·IIRCCS San Raffaele·Phase 1/2·NCT01730222·137 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Withdrawn·YYale University·Phase 2·NCT04045730

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Completed·—·Phase 2·NCT02723331·48 enrolled

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Completed·CClovis Oncology, Inc.·Phase 2·NCT01124786·367 enrolled

Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02514421·6 enrolled

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Withdrawn·UUniversity of Cincinnati·Phase 2·NCT00728000

65 more indications

Lymphoma10 trials

Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

Completed·UUniversity of Cologne·Phase 1/2·NCT00147875·60 enrolled

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06465446·202 enrolled

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02953509·178 enrolled

Show 7 more trials

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT02295722·100 enrolled

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06230224·216 enrolled

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT01359696·40 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT01564251·104 enrolled

Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00491127·10 enrolled

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Completed·RRoyal Marsden NHS Foundation Trust··NCT00301301·39 enrolled

Gemcitabine6 trials

Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT00452881·151 enrolled

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Recruiting·SShanghai Zhongshan Hospital··NCT07291063·50 enrolled

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

Completed·FFudan University·Phase 2·NCT01810367·84 enrolled

Show 3 more trials

Adjuvant Effect of Chloroquine on Gemcitabine

Completed·UUniversity of Zurich·Phase 1·NCT01777477·9 enrolled

HAI Abraxane With Gemcitabine and Bevacizumab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01057264·78 enrolled

Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer

Terminated·RRigshospitalet, Denmark·Phase 2·NCT00531687·8 enrolled

Lung Cancer6 trials

The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 3·NCT02283476·200 enrolled

Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00489983·91 enrolled

Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490659·13 enrolled

Show 3 more trials

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00870870·64 enrolled

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Completed·AAktion Bronchialkarzinom e.V.·Phase 3·NCT00148395·280 enrolled

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT01656551·232 enrolled

Solid Tumors4 trials

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting·VVerastem, Inc.·Phase 1/2·NCT07020221·295 enrolled

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Recruiting·VVasgene Therapeutics, Inc·Phase 2/3·NCT06493552·700 enrolled

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT00887757·46 enrolled

Show 1 more trial

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Terminated·AADC Therapeutics S.A.·Phase 1·NCT05389462·128 enrolled

Small Cell Lung Cancer4 trials

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00356525·41 enrolled

A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01005680·256 enrolled

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191490·162 enrolled

Show 1 more trial

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00087711·1,713 enrolled

Biliary Tract Cancer3 trials

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

Completed·—·Phase 2·NCT00123825·30 enrolled

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03779035·460 enrolled

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Patients With Advanced Solid Tumors3 trials

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT06041035·115 enrolled

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Completed·TTheriva Biologics SL·Phase 1·NCT02045602·42 enrolled

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Active, not recruiting·LLisata Therapeutics, Inc.·Phase 2·NCT05712356·67 enrolled

Cancer of the Pancreas3 trials

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005926·50 enrolled

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001431·20 enrolled

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00020345

Cholangiocarcinoma3 trials

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Terminated·QQED Therapeutics, a BridgeBio company·Phase 3·NCT03773302·48 enrolled

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Terminated·SStanford University·Phase 2·NCT01151761·2 enrolled

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Withdrawn·UUniversity of Louisville·Phase 3·NCT03081039

Adenocarcinoma3 trials

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

Completed·AAmer Zureikat·Phase 1/2·NCT01128296·35 enrolled

Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191503·30 enrolled

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Terminated·PPoint Therapeutics·Phase 2·NCT00116389·60 enrolled

Immunotherapy2 trials

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Unknown status·—·Phase 1/2·NCT04004234·20 enrolled

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT04630730·46 enrolled

Cervical Cancer2 trials

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT04697628·502 enrolled

Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients

Completed·PProfessor Fernando Figueira Integral Medicine Institute·Phase 2·NCT02309658·50 enrolled

Soft Tissue Sarcoma2 trials

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Completed·—·Phase 2·NCT00134641·40 enrolled

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06370871

Metastatic Urothelial Cancer2 trials

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Completed·IInstitut Claudius Regaud·Phase 2/3·NCT02240017·46 enrolled

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06592326·460 enrolled

Advanced Solid Tumors2 trials

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT03102320·173 enrolled

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Completed·TTraws Pharma, Inc.·Phase 1·NCT01165905·10 enrolled

Nasopharyngeal Carcinoma2 trials

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·FFudan University·Phase 2·NCT04517214·100 enrolled

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

Completed·MMinistry of Health, Malaysia·Phase 2·NCT00697905·18 enrolled

First Line Therapy2 trials

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruiting·SSun Yat-sen University·Phase 2/3·NCT04890522·622 enrolled

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03629925·357 enrolled

Hepatocellular Carcinoma2 trials

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00142467·33 enrolled

Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

Unknown status·—·Phase 2·NCT00844688·30 enrolled

Toripalimab1 trial

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Unknown status·LLu Wang, MD, PhD·Phase 2·NCT05350943·70 enrolled

Gallbladder Carcinoma1 trial

Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC

Completed·KKrankenhaus Nordwest·Phase 3·NCT03673072·68 enrolled

Clinical Trial1 trial

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Terminated·CCornerstone Pharmaceuticals·Phase 1/2·NCT00907166·6 enrolled

Non-squamous NSCLC1 trial

Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

Completed·AAktion Bronchialkarzinom e.V.·Phase 2·NCT00536640·224 enrolled

Peritoneal Cancer1 trial

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Completed· GSK logo

GSK·Phase 2·NCT00061308·75 enrolled

Pancreatic Surgery1 trial

Chemotherapy and Radiation Following Pancreatic Surgery

Completed·WWashington University School of Medicine·Phase 2·NCT00660270·53 enrolled

Randomized Controlled Trial1 trial

Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy

Completed·HHuazhong University of Science and Technology·Phase 3·NCT00644618·120 enrolled

Fallopian Tube Cancer1 trial

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed· Roche logo

Roche·Phase 2·NCT00096993·131 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Biliary Cancer1 trial

Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting·UUNICANCER·Phase 3·NCT05615818·800 enrolled

Overall Survival1 trial

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

Terminated· Amgen logo

Amgen·Phase 2·NCT00613730·3 enrolled

Ovarian Cancer1 trial

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

First-line1 trial

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled

Carcinoma of Unknown Primary1 trial

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135

Periampullary Cancer1 trial

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Completed·LLund University··NCT03724994·201 enrolled

Urothelial Carcinoma1 trial

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Active, not recruiting·—·Phase 1/2·NCT02202772·51 enrolled

Mantle Cell Lymphoma1 trial

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Completed·CCephalon·Phase 1·NCT01345357·24 enrolled

Metastatic1 trial

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01893801·25 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05498220·5 enrolled

HER2 Positive1 trial

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT07296705·25 enrolled

Advanced Cancers1 trial

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Completed·TTrishula Therapeutics, Inc.·Phase 1·NCT03884556·56 enrolled

HER2-positive Advanced Solid Tumors1 trial

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Unknown status·SSUNHO（China）BioPharmaceutical CO., Ltd.·Phase 1/2·NCT04934514·97 enrolled

Lenalidomide1 trial

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179751·50 enrolled

Nab-paclitaxel1 trial

Scheduling Nab-paclitaxel With Gemcitabine

Completed·CCCTU- Cancer Theme·Phase 2·NCT03529175·146 enrolled

Preoperative1 trial

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191126·263 enrolled

Triple-Negative Breast Cancer1 trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05382286·443 enrolled

Transitional Cell Carcinoma1 trial

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Withdrawn·OOncolytics Biotech·Phase 1·NCT02723838

Pancreatic Ductal Adenocarcinoma1 trial

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated· Novartis logo

Novartis·Phase 2·NCT04390763·164 enrolled

Glioma1 trial

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04051047

Synovial Sarcoma1 trial

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04145700·23 enrolled

Relapsed/Refractory1 trial

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Completed·—·Phase 1/2·NCT03052933·28 enrolled

Metastatic Solid Tumors1 trial

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01296568·3 enrolled

Chemotherapy1 trial

Chemotherapy and G-CSF for Mobilization

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03442673·137 enrolled

Pancreatic Carcinoma1 trial

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Completed·UUNICANCER·Phase 3·NCT02539537·171 enrolled

Metastatic Head and Neck Cancer1 trial

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00248560·36 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Withdrawn·GGeorgetown University·Phase 2·NCT06017297

Treatment1 trial

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Temporarily not available·PProvidence Health & Services··NCT05389514

Elderly Patients1 trial

Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Terminated·HHellenic Oncology Research Group·Phase 3·NCT00442026·106 enrolled

Safety and Efficacy1 trial

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02715531·243 enrolled

Pancreas Cancer1 trial

A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

Unknown status·AAHS Cancer Control Alberta·Phase 3·NCT01586611·175 enrolled

Advanced Cancer1 trial

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Completed· Bayer logo

Bayer·Phase 1·NCT01460537·50 enrolled

Patients With Solid Tumors1 trial

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, not recruiting·HHummingbird Bioscience·Phase 1·NCT05919537·68 enrolled

Induction Chemotherapy1 trial

Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT01973101·120 enrolled

Leiomyosarcoma1 trial

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting·IItalian Sarcoma Group·Phase 2·NCT04383119·100 enrolled

Bladder Carcinoma1 trial

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Completed·YYale University·Phase 2·NCT00461851·17 enrolled

Other Solid Tumors1 trial

Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors

Completed·WWashington University School of Medicine·Phase 1·NCT00660426·30 enrolled

Malignancy1 trial

Study of GemOx and Vandetanib in Advanced Solid Malignancy

Completed·LLeonard Appleman·Phase 1·NCT00660725·22 enrolled

Regulatory

FDA Approval Timeline[5]

May 15, 1996

GEMZAR

NDA NDA020509

Aug 4, 2011

GEMCITABINE HYDROCHLORIDE

NDA NDA200795

Aug 3, 2017

GEMCITABINE HYDROCHLORIDE

NDA NDA209604

Jul 16, 2018

INFUGEM

NDA NDA208313

Jun 27, 2025

AVGEMSI

NDA NDA219920

Sep 9, 2025

INLEXZO

NDA NDA219683

Sources

References

[1]
ClinicalTrials.gov — 1551 trial records for Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gemzar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219683). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Gemzar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Patent Landscape[6]

Patent Cliff

Jun 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12403086Jun 28, 2030

12576253Dec 17, 2030

8679094Apr 15, 2032

9241948Jul 1, 2033

10729823Aug 19, 2034

2 more patents

12447241Aug 19, 2034

12636300Nov 6, 2038